Nuvectis Q2 net loss widens to $7.0 million; $115 million raise extends cash runway
Nuvectis reported second-quarter 2026 results with a net loss of $7.0 million, up from $6.3 million a year earlier, and cash and cash equivalents of $22.2 million at June 30, 2026. The company said a July 2026 follow-on offering raised $115 million in gross proceeds, which it says extends its cash runway into the first half of 2029. The offering adds capital for shareholders, while the reported loss grew and cash on the June 30 balance sheet was well below the $31.6 million at December 31, 2025.
Key points
- Net loss was $7.0 million for the three months ended June 30, 2026, versus $6.3 million a year earlier; basic and diluted loss per share was $(0.30) in both periods.
- Cash and cash equivalents were $22.2 million at June 30, 2026, compared with $31.6 million at December 31, 2025.
- A July 2026 follow-on offering raised $115 million in gross proceeds, which includes the exercise of the underwriters' overallotment option.
- Ciprocopan (NXP100) was approved in China in July 2026 for PNH patients not previously treated with complement inhibitors; a U.S. IND submission is expected in 4Q2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.